Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Watch brief explainer videos focusing on science, research, and advances in cancer, featuring Dana-Farber Cancer Institute doctors and researchers.
COVID-19 Vaccine and Cancer: Reaching Communities of ColorThomas Farrington, a prostate cancer survivor and founder of the Prostate Health Education Network, as well as a trustee for Dana-Farber Cancer Institute in Boston, shares why he feels it's especially important for communities of color to trust, and have access to the COVID-19 vaccine. Video published: 2/23/21.
A Patient's Journey with EGFR-Mutant Lung CancerA triathlete shares her powerful journey fighting EGFR-mutant lung cancer. Pasi Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology and the Chen-Huang Center for EGFR- Mutant Lung Cancers, details the latest research into this disease. Video published: 1/27/21.
COVID-19: Study Shows Sharp Decline in Cancer Screenings and Diagnoses
Dana-Farber/Brigham and Women’s Cancer Center researchers document a substantial decline in cancer and precancer diagnoses at the Northeast’s largest health care system during the first peak of the COVID-19 pandemic because of a drop in the number of cancer screening tests performed. Dr. Ziad Bakouny explains in this video. View related news release. Video published: 1/15/21.
Dana-Farber Administers COVID-19 VaccinationsDana-Farber Cancer Institute has begun vaccinating clinical and non-clinical patient-facing staff for COVID-19. The Institute has a goal of 1,000 vaccines each week. Video published: 12/17/2020.
CAR T-cell Therapy for Lymphoma: A Patient's JourneyA patient with lymphoma shares her story about how she benefitted from a CAR-T clinical trial. Caron Jacobson, MD, MMSc, presented the results from that trial, ZUMA 5, at this year's ASH conference. Video published: 12/7/20.
Racial Disparities after Cancer SurgeryTrends in Racial Disparities in Mortality After Cancer Surgery, 2007-2016. New research led by Dr. Miranda Lam publishing in JAMA Network Open. Video published: 12/3/20.
New Liver Cancer Research at Dana-FarberDana-Farber Cancer Institute's Liver Cancer Center is advancing research and treatment opportunities for patients. Thomas Abrams, MD, highlights key studies. Video published: 11/24/2020.
Dana-Farber Research Looks at Blood Test to Detect Cancer
Dana-Farber’s Deb Schrag, MD, MPH, is leading the Pathfinder Study, a study that looks at a simple blood test and evaluates it to see if it could detect multiple cancer types at the earliest and most treatable stages. See related news release. Video published: 10/23/20.
Inflammatory Breast Cancer: A Patient’s JourneyPatient Nadege Vilnaigre details her journey with inflammatory breast cancer (IBC). Beth Overmoyer, MD, explains why this form of breast cancer is challenging and what the Inflammatory Breast Cancer Program at Dana-Farber offers patients like Nadege. Video published: 10/7/20.
Is Coffee Consumption Good for Advanced Colon Cancer?
A new study shows daily coffee consumption is associated with improved survival in patients with metastatic colorectal cancer. Dana-Farber’s Kimmie Ng, MD, MPH, is the senior author on the study published in JAMA Oncology. Read news release. Video published: 9/17/2020.
Reimagining Immunotherapy in Head and Neck CancerDana-Farber Cancer Institute's Glenn J. Hanna, MD, and Rizwan Romee, MD, are conducting one of the first studies using modified natural killer cells, which are natural to the body's immune system, to fight advanced head and neck cancer in patients. Video published: 9/8/2020.
New Research Offers Hope to Those With Corneal Blindness
Researchers from Dana-Farber Cancer Institute, Massachusetts Eye and Ear, and Boston Children's Hospital have developed a new procedure called cultivated autologous limbal epithelial cell transplantation (CALEC) that offers hope for patients with corneal blindness in one eye. Read news release. Video published: 9/1/2020.
Prostate cancer: Is there a future for immunotherapy?Dana-Farber Cancer Institute's Christopher Sweeney, MBBS, discusses recent immunotherapy research in prostate cancer and if immunotherapy in advanced prostate cancer has a future. Published 8/25/20.
New Treatments for Bladder CancerBladder cancer therapies, once very limited, now offer more options to treat patients than ever before. Guru Sonpavde, MD, director of Dana-Farber’s Bladder Cancer Program, details new treatments and research initiatives on the horizon for bladder cancer.
New Research on Hodgkin Lymphoma at Dana-Farber
Margaret Shipp, MD, explains new research that looks at the mechanism by which PD-1 blockade works in Hodgkin lymphoma. Study in Nature Medicine. Video published: 8/10/20.
Full-Time Doctor, Part-Time Hollywood WriterRoshan Sethi, MD, details how his passion for helping others led him to become a radiation oncologist at Dana-Farber/Brigham and Women's Cancer Center while simultaneously co-creating the hit medical TV drama The Resident on FOX.
Prostate Cancer Research Links Spread of Disease to Epigenetics
Prostate Cancer Research Links Spread of Disease to Epigenetics
Matthew Freedman, MD, details a prostate cancer study in Nature Genetics that links metastasis to the revival of a molecular program that went dormant during fetal development. Story published on July 20th, 2020 in Nature Genetics .
Making Music After Throat Cancer: A Patient's Journey
Dana-Farber doctors developed a personal approach to treat Keisuke Wakao's throat cancer, which threatened both his life and his career as assistant principal oboist for the Boston Symphony Orchestra. Today he is cancer-free and sharing his journey as well as his beautiful music. Keisuke also shared his story during a TEDx talk: Playing for Life: Keisuke Wakao. Story published: 7/1/2020.
Prostate Cancer Research: Launching a Study During the COVID-19 PandemicDana-Farber Cancer Institute's Dr. Christopher Sweeney discusses the importance of prostate cancer research during the coronavirus global pandemic, and the challenges of launching an international trial during this time. Published on 6/4/2020.
CAR-T Research: Follicular Lymphoma and Marginal Zone LymphomaCaron Jacobson, MD, explains new research presented at ASCO20 in the use of CAR-T therapy for follicular lymphoma and marginal zone lymphoma. Promising results from a phase-2 clinical trial called ZUMA 5 showed significant and durable clinical benefits. Published on May 29, 2020.
Kidney Cancer Research: Immunotherapy Combinations in Rare Kidney CancersDana-Farber Cancer Institute researchers say a study that combined immunotherapy with a veg-f therapy shows promise in rare kidney cancers. The study published in the Journal of Clinical Oncology. Published on April 15, 2020.
COVID-19: Information for Cancer Patients Answers to some questions cancer patients may have about COVID-19. Published on 3/20/2020.
Colorectal Cancer in Young Adults: A Patient's Story A Dana-Farber patient opens up about getting diagnosed with advanced colon cancer at age 34. Dr. Kimmie Ng, director of the Young-Onset Colorectal Cancer Center at Dana-Farber/Brigham and Women's Cancer Center talks about research that is focused on getting to the bottom of an alarming trend - an increasing rate of colorectal cancer cases diagnosed in adults younger than 50 years old.
Immunotherapy Research in Head and Neck Cancer Immunotherapy in recurrent and metastatic head and neck cancers is now a part of standard care. Dana-Farber researchers are now investigating using those immunotherapies earlier, before the head and neck cancer spreads or comes back.
Pancreatic Cancer: New Treatment and Research OpportunitiesDana-Farber/Brigham and Women’s Cancer Center is the first center in New England to offer magnetic resonance imaging or MRI-guided radiation therapy technologies. This video explores what that means for pancreatic cancer patients.
Dana-Farber's Eric P. Winer, MD, Explains Results of HER2CLIMB TrialThis trial looks at a new breast cancer drug called tucatinib, combined with standard therapies. Results presented at SABCS 2019.
Kidney Cancer Patient Living Longer Thanks to Work of Nobel LaureateFrom bench side to bedside, meet the Dana-Farber patient who is living longer thanks to Nobel Laureate Bill Kaelin's research. Shaun Tierney and his oncologist, Dana-Farber's Dr. Toni Choueiri explain the clinical implications of drugs made possible through Dr. Kaelin's work.
ASH 2019: Improving Global Lymphoma Diagnoses Dana-Farber's Dr. David Weinstock explains research in Guatemala into increasing affordability and accessibility of diagnostics in lymphoma. Research presented at ASH 2019.
Male Breast Cancer Research and Advances Jose Pablo Leone, MD, a Dana-Farber breast cancer physician, explains the recent draft guidance by the FDA aimed at encouraging the inclusion of male patients in breast cancer trials.
Esophageal Cancer Milestone: Patient Marks 100th Treatment Metastatic esophageal cancer patient on a clinical trial at Dana-Farber Cancer Institute marks 100th cycle of chemotherapy and 5 years of the treatment that doctors credit with his complete response.
Dana-Farber's William Kaelin wins Nobel Prize Dr. William Kaelin's research dates back nearly 3 decades – his laboratory focusing on why mutations in genes known as tumor-suppressor genes can lead to cancer. He and two other scientists share the Nobel Prize for deciphering the mechanism that enables cells to sense and adapt to changes in oxygen abundance.
Stem Cell Patient Meets His DonorBack in 2005, Steve Collins was the 1000th Dana-Farber/Brigham and Women’s Cancer Center patient to receive stem cells from an unrelated donor. Shortly before meeting his donor face-to-face, the Institute marked its 10-thousandth unrelated stem cell transplant.
HPV-related Head and Neck Cancer ResearchA research trial at Dana-Farber Cancer Institute is looking at de-intensification as a possible treatment option for patients diagnosed with HPV-related head and neck cancer. Dr. Robert Haddad explains in this video.
Brain Cancer Project: Count Me InCount Me In, a non-profit patient-partnered research initiative, has launched the Brain Cancer Project. Stewarded by Dana-Farber Cancer Institute, the Emerson Collective, the Broad Institute of MIT and Harvard, and with the Minderoo Foundation, the Brain Cancer Project is aimed at accelerating discoveries.
Bile Duct Cancer: A Patient's JourneyA bile duct (cholangiocarcinoma) patient and her doctor, Dana-Farber's Douglas Rubinson, MD, detail the ups and downs of her journey as well as the latest research into bile duct cancer.
Breast Cancer Research: A Focus on Older Women Dr. Eric Winer explains the need for an increased focus on studying older women with breast cancer and why the research pendulum is starting to swing in their direction.
Dana-Farber Recognized for Excellence in Nursing PracticeDana-Farber Cancer Institute has been awarded Magnet® status from the American Nurses Credentialing Center (ANCC) for the fourth consecutive time. This prestigious designation recognizes excellence in nursing practice and health care delivery and has been awarded to only 8% percent of hospitals in the United States.
Managing Cancer Pain in the Face of Substance Use DisordersA metastatic breast cancer patient with a history of substance use disorder candidly shares her story and challenges of balancing her past with her need for pain management for her cancer.
Advances in Pancreatic Cancer ResearchDana-Farber's Thomas Abrams, MD, details advances in pancreatic cancer research and treatment options. Learn more about our expertise treating pancreatic cancer at https://www.dana-farber.org/pancreatic-cancer/.
Lymphoma chemotherapy drug also acts as immunotherapy, new research finds Dana-Farber researchers find large doses of a 60 year-old chemotherapy drug used in certain lymphomas not only kills cancer cells directly, but also spurs an immune system attack on the cells. David Weinstock, MD, explains the research.
Breast Cancer Treatment Options Before SurgeryEric Winer, MD, director of Dana-Farber Breast Oncology Program says that breast cancer therapy has changed dramatically during the last 20 years. One big area of change is giving more systemic, medical therapies like chemotherapy or hormonal therapy before breast cancer surgery, rather than after.
Prostate Cancer: Research Shows New Treatment Option Offers Improved Survival A new option for men with metastatic hormone-sensitive prostate cancer that researchers say is superior to the current standard therapy. Dana-Farber's Christopher Sweeney, MBBS, explains. Research presented at #ASCO19 and published in the New England Journal of Medicine.
Count Me In: Patients Partner with Researchers to Study Cancer“Count Me In” is a non-profit that offers a new model of patient-partnered research. This video features an interview with Dr. Nikhil Wagle who explains how it's changing how researchers study cancer and how patients can get involved.
Vitamin D Benefit in Advanced Colorectal CancerDana-Farber Cancer Institute researchers say first of its kind study shows high-dose vitamin D benefit in patients with advanced colorectal cancer. Results prompt large phase 3 trial. For more information: http://ms.spr.ly/6054TGKLn
Precision Cancer Medicine: Dr. Benjamin Izar Named a ‘NextGen Star’ by AACRUnlocking cancer’s mysteries one cell at a time, Dana-Farber’s Dr. Benjamin Izar is being recognized by the American Association for Cancer Research as a ‘NextGen Star’ for his work in precision medicine and understanding a tumor’s unique ecosystem.
Kidney Cancer: Immunotherapy Combination Shows PromiseNew hope for kidney cancer patients and it comes in the form of an immunotherapy drug combined with a targeted agent. Dana-Farber Cancer Institute researchers say this drug combination could become a new standard, first-line treatment for patients with metastatic kidney cancer.
Low-risk Prostate Cancer Patients Opting for Conservative ApproachAn upsurge in a conservative approach to treating low-risk prostate cancer patients, according to a study led by radiation oncologists from Dana-Farber/Brigham and Women’s Cancer Center. Instead of undergoing surgery or radiation, many men are choosing to be closely monitored by their doctors.
Tumor Profiling for Ovarian Cancer: One Woman’s StoryNo two cancers are created equal and that’s why the PROFILE research project launched - to help guide doctors in personalizing treatment for patients. And while every case is different, for one grandmother, the decision to have her tumor profiled was life-changing.
Immunotherapy May Be Effective for Triple-negative Breast CancerA recent study shows that for the first time, immunotherapy may be effective for treating triple-negative breast cancer. Dana-Farber Cancer Institute's Dr. Eric Winer explains why this is one of the biggest advances in the treatment of triple-negative breast cancer in years.
Dana-Farber Researchers Win Grand Challenge for Colorectal Cancer ResearchA tremendous boost for scientists looking to unlock the secrets of microbiota’s role in colorectal cancer. A research team led by Dana-Farber Cancer Institute’s Dr. Matthew Meyerson and Dr. Wendy Garrett, also of the Harvard T.H. Chan School of Public Health, won Grand Challenge funding from Cancer Research UK in the amount of up to $25 million.
Immunotherapy and Bladder CancerResearchers at Dana-Farber Cancer Institute are looking to expand treatment options for bladder cancer patients beyond surgery and chemotherapy. In what’s known as the BLASST trial, they’re adding in immunotherapy before any surgery takes place in muscle-invasive bladder cancer.
Personalized Vaccine to be Tested for the First Time in Patients with Kidney CancerDoctors at Dana-Farber Cancer Institute are taking personalized cancer care to the next level, working to develop custom-made vaccines for kidney cancer.
Center for Protein Degradation at Dana-FarberDr. Nathanael Gray and Dr. Eric Fischer explain the impact of the new Center for Protein Degradation at Dana-Farber Cancer Institute.
Trial Aims to Treat Kidney Cancer Tumor Before SurgeryA clinical trial is looking at a new way to treat kidney cancer – using drug therapies to treat the tumor first, before surgery - in the hope that the T cells will remember what to do in case any of the cancer comes back.
Obesity, Women, and Colorectal CancerColorectal cancer rates overall are going down, but for one group – younger patients – the opposite is true. And in a study published in JAMA ONCOLOGY, for younger women who are also obese, researchers say they’ve uncovered a worrisome trend.
Breaking Down Barriers to Getting a MammogramMammograms can be the first line of defense in detecting breast cancer - but some women don't get one because they can't get to the doctor. Dana-Farber's Mammography Van aims to eliminate barriers by bringing this life-saving tool directly to women in their communities.
Expanded Treatment Options for Acute Myeloid Leukemia (AML)For patients diagnosed with acute myeloid leukemia or AML, traditional chemotherapy treatment options can’t be endured by many elderly patients. In a recent study, Dana-Farber Cancer Institute’s Dr. Anthony Letai explains that the drug Venetoclax, combined with another drug, Azacytidine, might offer an effective treatment option that will be easier to tolerate. The FDA recently granted accelerated approval for Venetoclax for such AML patients.
Breast Cancer Surgery and Impact on Quality of Life in Young WomenNew research released by Dana-Farber/Brigham and Women's Cancer Center shows more young women with breast cancer opting to have mastectomies even as many experience a persistent decline in their sexual and psychosocial well-being. The findings were just presented at the San Antonio Breast Cancer Symposium.
Improving Outcomes for Myeloid CancersImproving outcomes for myeloid cancer patients who undergo stem cell transplantation is a focus of several studies presented by Dana-Farber Cancer Institute scientists at the American Society of Hematology Annual Meeting.
Myeloma: Immune Response May Predict ProgressionBefore symptoms of multiple myeloma develop, Dana-Farber Cancer Institute researchers say a patient’s risk of progression might be tied to certain precursor conditions. The findings were presented at the American Society of Hematology Annual Meeting.
Breakthrough for Young Man Treated for Sickle Cell DiseaseAn incredible breakthrough for a young man treated for sickle cell disease at the Dana-Farber/Boston Children’s Cancer and Blood Disorder Center. Doctors announce first success story from a new gene therapy strategy.
Ovarian Cancer: Past, Present, FuturePatients diagnosed 34 years apart share their journey with ovarian cancer - reflecting on advances, similarities, and work that still needs to be done. They're brought together by their efforts for Dana-Farber's Susan F. Smith Center for Women's Cancers Executive Council.
Metastatic HPV-linked Head and Neck Cancer StudyStudy findings in metastatic HPV-linked head and neck cancer may help guide treatment. Findings published in JCI Insight show better survival rates for some patients. After analyzing tumor DNA, they found these patients have certain mutations in a particular pathway.
Boston News Reporter Opens Up About Breast CancerBoston-based television reporter Kelli O'Hara opens up about her journey with breast cancer, the challenges she's facing as a younger woman balancing career and treatment, and her desire to one day have a family.
The Metastatic Prostate Cancer Project - Giving a Voice to Prostate Cancer Patients“Count Me In” is a new nonprofit organization aiming to partner patients directly with researchers for a number of cancers, including metastatic prostate cancer. For prostate cancer patients, it’s a way to give a voice to a disease that men typically don’t like to talk about. To learn more: https://joincountmein.org
Chemical Biology: Small Molecules Making a Big ImpactA look inside the growing Chemical Biology program at Dana-Farber Cancer Institute. Program Director Dr. Milka Kostic takes you into the labs where chemists and biologists work side-by-side, making and testing small molecules. They're seeking out what might be driving a cancer tumor and the hope is, these molecules might someday be powerful cancer-fighting drugs.
Chemotherapy or No Chemotherapy in Breast CancerNew findings announced this year show many women with the most common type of breast cancer can confidently skip chemotherapy. Dr. Eric Winer, chief of Dana-Farber Cancer Institute's Breast Oncology Treatment Center, breaks down what women need to know.
Rare Genitourinary Cancer Imagine having a cancer so rare, trials don't exist for you. That's been the case for years for patients with certain genitourinary cancers. Now, a first of its kind trial at Dana-Farber Cancer Institute offers a potential turning point and the opportunity to try a promising therapy.
Coding for CancerForget Silicon Valley, these women chose Dana-Farber Cancer Institute, working with some of the top minds in cancer genomics. Oncologists and computational biologists come together to analyze sequenced tumors in the hopes of matching tumors with targeted therapies.
Study Aims to Help Breast Cancer Patients Emotionally RecoverCancer survivors know the journey doesn’t end when treatment ends. That’s especially true for young breast cancer survivors, who often report feeling isolated and anxious. Doctors at Dana-Farber Cancer Institute are looking at mindfulness meditation and survivorship education as part of the "Pathways to Wellness" study.
Diet Linked to Bacteria and Certain Types of Colorectal CancerDana-Farber Cancer Institute researchers looked at the link between diet, gut-health, and colorectal cancers. They found the risk of certain cancers went up if people were eating diets high in red and processed meat, refined grains, and sugar. The study was published in the October 2018 issue of "Clinical Gastroenterology and Hepatology."
New Guidelines for Colorectal Cancer ScreeningDana-Farber Cancer Institute's Dr. Jeffrey Meyerhardt explains why "45" is the new important age when it comes to getting screened for colorectal cancer.
60-year-old Medical Mystery Surrounding Thalidomide Solved More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists at Dana-Farber Cancer Institute have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?
Cameron Smith Returns to Dana-FarberForty years after being treated for pediatric cancer, Cameron Smith returned to Dana-Farber in an emotional homecoming, and shared a message of hope. Victoria Warren reports for Dana-Farber Cancer Institute.
Request a Publication
Receive by mail the current issue of a Dana-Farber publication by completing this request form.
Find facts, figures, and useful information about Dana-Farber's operations and services, including statistics about outpatient visits, clinical trials, patient volume, financial results, and much more.